Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis.

@article{Whittle2011CirculatingBA,
  title={Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis.},
  author={Robert M Whittle and Peter C Taylor},
  journal={Blood},
  year={2011},
  volume={118 24},
  pages={6446-9}
}
Extracorporeal photopheresis (ECP) is an important therapeutic option in steroid-refractory chronic graft-versus-host disease (cGVHD). Few biomarkers predicting response exist. We measured serum B-cell activating factor (BAFF) in 46 cGVHD patients receiving ECP before and during treatment course. BAFF level at 1 month of ECP predicted 3- and 6-month skin disease response, with BAFF less than 4 ng/mL associated with significant skin improvement and complete resolution in 11 of 20 patients. High… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Biomarkers in chronic graft-versus-host disease: quo vadis?

Bone Marrow Transplantation • 2018
View 3 Excerpts

Guidelines on the use of extracorporeal photopheresis

Journal of the European Academy of Dermatology and Venereology : JEADV • 2014

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2011
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…